Duloxetine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Also note: drug.original_indications and taiwan_regulatory.licenses are both empty, so “Original Indication” cannot be sourced from Taiwan regulatory data as instructed — I did not guess it. Instead I cited the one place original indications actually appear in this evidence pack (the PMID 31749717 abstract, itself provided data, not external knowledge), and labeled it clearly as such rather than presenting it as a confirmed local label indication.
Duloxetine: From Major Depressive Disorder to Benign Paroxysmal Torticollis of Infancy
One-Sentence Summary
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI), globally known for treating major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, and fibromyalgia (per literature cited in this evidence pack). The TxGNN model’s top-ranked prediction for this drug is Benign Paroxysmal Torticollis of Infancy, with a prediction score of 99.85%, but 0 clinical trials and 0 publications currently support this specific direction — it is a pure model prediction with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the Taiwan/EU regulatory dataset (drug currently not marketed, 0 licenses on record). Per literature context within this evidence pack (PMID 31749717), Duloxetine is known to be approved elsewhere for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, and fibromyalgia. |
| Predicted New Indication | Benign Paroxysmal Torticollis of Infancy |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 |
| EU Market Status | Not marketed (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action (MOA) data for Duloxetine is currently unavailable and is flagged as a blocking-adjacent data gap in this evidence pack (DG002). Based on known pharmacological class information, Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI), a class whose efficacy has been proven in mood and anxiety disorders and certain chronic pain states; mechanistically it acts on monoamine reuptake rather than on developmental or vestibular pathways.
Benign paroxysmal torticollis of infancy is a self-limiting condition occurring in infancy, thought to be related to immature vestibular system development or to sit within the migraine spectrum. There is no established pharmacological or mechanistic link between SNRI activity and this condition, and no safety data exist for Duloxetine in this age group.
The TxGNN model assigned this pairing a very high similarity score, but that score reflects graph-embedding proximity rather than a validated biological rationale. Given the absence of any supporting mechanistic literature, trial data, or age-appropriate safety data, this specific prediction should be treated as a low-confidence, hypothesis-generating signal only, not as clinically actionable.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No marketing authorizations are on record for Duloxetine (DB00476) in this jurisdiction — the drug is currently listed as not marketed (0 licenses).
Safety Considerations
Please refer to the SmPC for safety information.
(Key warnings, contraindications, and drug-drug interaction data are all marked as data gaps or “not found” in this evidence pack; TFDA label warnings/contraindications retrieval is tracked as a blocking data gap, DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has evidence level L5 — a model prediction with no supporting clinical trials, no literature, and no plausible mechanistic link to the drug’s known SNRI pharmacology. Combined with the absence of any regulatory safety data (DG001, blocking) and MOA confirmation (DG002), there is currently no basis to advance this specific indication beyond exploratory research.
To proceed, the following is needed:
- TFDA/SmPC label data (warnings, contraindications) — required before any safety screening (blocking gap DG001)
- Confirmed mechanism of action from DrugBank or equivalent source (DG002)
- Preclinical or mechanistic rationale connecting SNRI activity to vestibular/migraine-spectrum pathophysiology, if this candidate is to be pursued further
- Note: within this same prediction batch, other candidates for Duloxetine show substantially stronger evidence and may warrant priority review instead — notably obsessive-compulsive disorder (L2, includes a completed Phase 4 trial NCT00464698 and a double-blind RCT, PMID 27811556) and agoraphobia (L4, supported by open-label and cohort literature on panic disorder). These were not the top-ranked TxGNN score but have meaningfully more clinical grounding than the rank-1 candidate covered above.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.